J&J announced that is discontinuing its phase 3 trial of ustekinumab in #SLE. An interim analysis of the 516 pt LOTUS trial showed no new safety concerns. Study was halted for lack of efficacy. A subsequent LOTUS-C trial in China has been suspended. https://t.co/iN5trI0V71